| Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis YH Yeo, HJ Ho, HI Yang, TC Tseng, T Hosaka, HN Trinh, MS Kwak, ... Gastroenterology 156 (3), 635-646. e9, 2019 | 14 | 2019 |
| Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial T Sriprayoon, C Mahidol, T Ungtrakul, P Chun‐on, K Soonklang, ... Hepatology Research 47 (3), E161-E168, 2017 | 12 | 2017 |
| Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients T Ungtrakul, T Sriprayoon, P Kusuman, P Chunnuan, K Soonklang, ... Medicine 96 (13), 2017 | 10 | 2017 |
| Andrographis paniculata: Dissolution investigation and pharmacokinetic studies of four major active diterpenoids after multiple oral dose administration in healthy Thai volunteers N Pholphana, D Panomvana, N Rangkadilok, T Suriyo, P Puranajoti, ... Journal of ethnopharmacology 194, 513-521, 2016 | 7 | 2016 |
| A simple and sensitive LC-MS/MS method for determination of four major active diterpenoids from Andrographis paniculata in human plasma and its application to a pilot study N Pholphana, D Panomvana, N Rangkadilok, T Suriyo, T Ungtrakul, ... Planta medica 82 (01/02), 113-120, 2016 | 7 | 2016 |
| Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area T Ungtrakul, C Mahidol, P Chun-On, C Laohapand, S Siripongsakun, ... World journal of gastroenterology 22 (34), 7806, 2016 | 5 | 2016 |
| A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu … U Wiedermann, AJ Good, E Garner-Spitzer, Y Chao, I Bulat, ... Journal of Clinical Oncology 37 (4_suppl), TPS176-TPS176, 2019 | 2 | 2019 |
| Clinical parameters following multiple oral dose administration of a standardized Andrographis paniculata capsule in healthy Thai subjects T Suriyo, N Pholphana, T Ungtrakul, N Rangkadilok, D Panomvana, ... Planta medica 83 (09), 778-789, 2017 | 2 | 2017 |
| Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis S Chujan, T Suriyo, T Ungtrakul, Y Pomyen, J Satayavivad Biomedical Reports 9 (1), 42-52, 2018 | 1 | 2018 |
| Efficacy of Trastuzumab in HERZ-Positive Early Breast Cancer in Thai Patients: A Single Institution Experience P Patanayindee, K Soonklang, T Ungtrakul Journal of the Medical Association of Thailand 101 (6), 101, 2018 | 1 | 2018 |
| Human papillomavirus (HPV) in young patients with head and neck squamous cell carcinoma. T Ungtrakul, S Keelawat, C Vinayanuwattikun, V Sriuranpong Journal of Clinical Oncology 31 (15_suppl), e17004-e17004, 2013 | 1 | 2013 |
| 150P A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or … Y Chao, M Maglakelidze, LV Bulat, T Yau, S Tanasanvimon, ... Annals of Oncology 30 (Supplement_9), mdz422. 027, 2019 | | 2019 |
| 397P Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients T Ungtrakul, K Soonklang, J Dechma, P Kusuman, W Pongpun Annals of Oncology 30 (Supplement_9), mdz432. 006, 2019 | | 2019 |
| 1212P Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety … U Wiedermann, E Garner-Spitzer, Y Chao, I Bulat, A Dechaphunkul, ... Annals of Oncology 30 (Supplement_5), mdz253. 038, 2019 | | 2019 |
| A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity … U Wiedermann, E Garner-Spitzer, Y Chao, I Bulat, A Dechaphunkul, ... CANCER RESEARCH 79 (13), 2019 | | 2019 |
| A phase 1b study of IMIJ-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or … M Maglakelidze, T Yau, I Bulat, C Yen, Y Chao, L Bai, A Good, N Ede, ... ANNALS OF ONCOLOGY 30, 123-123, 2019 | | 2019 |
| SO-004 A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or … M Maglakelidze, T Yau, I Bulat, C Yen, Y Chao, L Bai, A Good, N Ede, ... Annals of Oncology 30 (Supplement_4), mdz157. 003, 2019 | | 2019 |
| Abstract CT059: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety … U Wiedermann, E Garner-Spitzer, Y Chao, I Bulat, A Dechaphunkul, ... Cancer Research 79 (13 Supplement), CT059-CT059, 2019 | | 2019 |
| A COMPARISON OF RISK SCORE MODELS TO PREDICT THE RISK OF HCC IN CHRONIC HEPATITIS B PATIENTS IN THAILAND: IDDF2019-ABS-0051 T Kamalapirat, T Ungtrakul, K Soonklang, J Dechma, P Chunnuan, ... Gut 68, 2019 | | 2019 |
| IDDF2019-ABS-0051 A comparison of risk score models to predict the risk of HCC in chronic hepatitis b patients in thailand T Kamalapirat, T Ungtrakul, K Soonklang, J Dechma, P Chunnuan, ... Gut 68 (Suppl 1), A126-A126, 2019 | | 2019 |
